Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.75 -0.55%

-$0.29 today

Market cap
$3.71B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.30M

Average 1.16M

XENE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Xenon Pharmaceuticals Inc.NASDAQ: XENE

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $95.65M rose 24.1% year over year, behind the +36.1% change in trailing-twelve-month research & development. Sequentially, it fell 3.6% from the prior quarter. Over 3 fiscal years it compounded at +41.7% a year.

Context

  • Research & development amounted to 4012.5% of revenue in FY2025.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +24.1% toward the trailing-twelve-month pace of +36.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$95.65M-3.6% QoQ
Last fiscal yearDec 2025
$300.94M+43.0% YoY
LTMSep 2026
$371.08M+36.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.1%——
1 year+43.0%——
3-year CAGR+41.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
300.94M USD
Year-over-year change
+43.0%
4-year CAGR
+41.3%

Research & Development vs competitors

How XENE compares with its peers on the latest reported figures

  • XENE's LTM Sep 2026 research & development of $371.08M is the 4th highest of the 11 companies compared; the peer median is $238.49M.
  • Its year-over-year change of +36.1% is the 2nd highest of 11, against a peer median of -3.7%.
  • Over three fiscal years its annual growth of +41.7% compares with a peer median of +15.7%.
XENE Competitors Peer median
Research & Development for XENE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.23B +30.7%+29.9%33.3%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$623.61M -26.8%+9.9%13.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$400.72M -3.9%+5.3%11118.8%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$371.08M +36.1%+41.7%—
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$319.46M -7.3%-3.1%26.6%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$289.11M +17.6%+19.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M -3.5%+46.8%24.2%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M +58.7%+118.3%539.7%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$31.8M -27.0%-0.3%—
Peer median (excluding XENE) $238.49M-3.7%+15.7%26.6%

Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.44M9.43M007.5M
Cost of Revenue00167.51M2.56M2.54M
Gross Profit18.44M9.43M(167.51M)(2.56M)4.96M
Gross Margin100.0%100.0%——66.1%
Research & Development75.46M105.77M167.51M210.39M300.94M
Selling, General & Admin21.97M32.81M46.54M68.9M79.63M
Operating Expenses97.43M138.58M46.54M276.74M378.03M
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
EBITDA(78.09M)(127.74M)(210.51M)(235.86M)(342.35M)
EBITDA Margin-423.5%-1354.0%——-4564.7%
Operating Income(78.99M)(129.14M)(214.05M)(279.3M)(373.07M)
Operating Margin-428.4%-1368.9%——-4974.3%
Interest Income466K8.71M27.62M41.94M26.83M
Interest Expense00000
Other Income / Expenses105K3.89M31.37M40.88M28.18M
Income Before Tax(78.89M)(125.26M)(182.69M)(238.42M)(344.89M)
Pre-Tax Margin-427.9%-1327.7%——-4598.6%
Income Tax Expense(6K)118K(292K)(4.09M)1.02M
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Net Margin-427.8%-1328.9%——-4612.1%
EPS (Basic)(1.77)(2.06)(2.73)(3.01)(4.36)
EPS (Diluted)(1.77)(2.06)(2.73)(3.01)(4.36)
Weighted Avg Shares43.63M60.54M66.89M77.89M79.25M
Weighted Avg Shares (Diluted)43.63M60.54M66.89M77.89M79.25M

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Intrinsic Alpha fair value

Locked

Current Price

$37.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.